Unknown

Dataset Information

0

Ofatumumab - a valid treatment option for chronic lymphocytic leukemia patients.


ABSTRACT: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody's therapeutic effect on chronic lymphocytic leukemia.

SUBMITTER: AlDallal SM 

PROVIDER: S-EPMC5530057 | BioStudies | 2017-01-01

SECONDARY ACCESSION(S): 10.2147/TCRM.S140023

REPOSITORIES: biostudies

Similar Datasets

2011-01-01 | S-EPMC3262343 | BioStudies
2020-01-01 | S-EPMC7430864 | BioStudies
2010-01-01 | S-EPMC3262337 | BioStudies
2018-01-01 | S-EPMC5889503 | BioStudies
2012-01-01 | S-EPMC3627333 | BioStudies
2013-01-01 | S-EPMC3638632 | BioStudies
2011-01-01 | S-EPMC4916553 | BioStudies
2011-01-01 | S-EPMC3622251 | BioStudies
2014-01-01 | S-EPMC4571984 | BioStudies
2013-01-01 | S-EPMC3894149 | BioStudies